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A B S T R A C T
Objective: To estimate the prevalence of 35delG and Met34Thr variants in a Portuguese children’s
community sample and to compare these frequencies with nonsyndromic hearing-loss patients.
Methods: 502 children were randomly selected among the 8647 participants of the Portuguese birth
cohort Generation XXI, and screened for Met34Thr and 35delG variants in the GJB2 gene. These variants
were also studied on 89 index-cases, observed in the Clinic of ‘‘Hereditary Hearing-loss’’ in Saint John’s
Hospital Center, presenting a mild to profound nonsyndromic hearing-loss.
Results: Among the 502 children from Generation XXI, 10 were heterozygous for the 35delG variant (95%
Conﬁdence Interval 1.03–3.68) and 1 homozygous (95% Conﬁdence Interval 0.01–1.24). Other 10
children presented heterozygosity for the Met34Thr variant (95% Conﬁdence Interval 1.03–3.68). No
homozygous for the Met34Thr or compound heterozygotes (35delG/Met34Thr) were found. In the total
of 89 nonsyndromic hearing-loss patients, 5 (95% Conﬁdence Interval 2.11–12.8) were heterozygous and
7 (95% Conﬁdence Interval 3.61–15.6) were homozygous for the 35delG variant. The Met34Thr variant
was found in 4 patients, 2 heterozygous (95% Conﬁdence Interval 0.13–8.31) and 2 homozygous (95%
Conﬁdence Interval 0.13–8.31).
Conclusion: The carrier frequency of 35delG and Met34Thr variants in a Portuguese sample was 1 in 50.
Our data suggests that the 35delG mutation has an association with deafness. For the Met34Thr variant,
no association was observed. However, Met34Thr seemed to conform to an additive model in hearing-
loss.
 2015 Elsevier Ireland Ltd. All rights reserved.
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Hearing-loss (HL) is a very common congenital sensory
impairment, affecting approximately 1 in 500 to 1000 newborns
[1]. HL can be syndromic (30%) or nonsyndromic (70%) [2].
Nonsyndromic hearing-loss (NSHL) can be inherited in an
autosomal dominant trait in 15–20% of the cases, in an autosomal* Corresponding author. Tel.: +35 1225513647.
E-mail address: mariana.doria.ps@gmail.com (M. Do´ria).
http://dx.doi.org/10.1016/j.ijporl.2015.09.046
0165-5876/ 2015 Elsevier Ireland Ltd. All rights reserved.recessive trait (80%), or also X-linked (2–3%) or mitochondrial (1%)
[2]. More than 50% of cases of autosomal recessive NSHL in several
world populations are attributed to mutations in the GJB2 gene [3].
GJB2 encodes gap junction protein connexin 26 (Cx26), which has
been implicated in the maintenance of K+ homeostasis in the inner
ear [4].
1.1. Molecular genetics
The most common mutation in the GJB2 gene is a deletion of a
single guanine in a track of six guanines known as 35delG [2,5]. It is
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with a prevalence of 15.9% [6].
Overall, in the European general population, a high frequency of
carriers of the 35delG variant was also detected, with a frequency
of 1 in 51 (1.96%) [7]. For many years, it was established that the
highest carrier frequencies of 35delG in Europe were found in
countries close to the Mediterranean (1 in 31; 3.2%) [5,8], but
recent studies demonstrated that the highest carrier rates may
actually be found in Belarus (1 in 17; 5.8%) and Estonia (1 in 22;
4.5%) [3,9]. To our knowledge, there is only one study estimating
the carrier frequency of 35delG in 178 individuals from a
Portuguese population in about 1 in 45 (2.2%) [8].
Another variation in the GJB2 gene that has been found with a
high prevalence in studies in NSHL populations, including Portugal,
c.101 T ! C (Met34Thr), a methionine-to-threonine substitution at
amino acid 34 [2,6,10]. This variant was found at a lower frequency
in NSHL patients, compared to the 35delG mutation [11]. However,
in the general Caucasian population, several studies have found a
higher frequency of the Met34Thr variant [12,13]. A carrier rate of
approximately 1 in 37 (2.69%) for the Met34Thr variation and
approximately 1 in 73 (1.36%) for the 35delG mutation was found
in a United Kingdom (UK) study [14]. To our knowledge, no
published studies in the Portuguese population have estimated the
carrier rate of this variant, but studies in Europe demonstrated very
different carrier frequencies among countries, about 1 in 25 (4%) in
Britain/Ireland and Finland, 1 in 43 (2.3%) in France and 1 in 17
(5.8%) in Estonia [9,13,15].
1.2. Clinical genetics
The degree of NSHL in 35delG homozygotes has already been
widely documented by several studies, stating that these individuals
usually present moderate to profound NSHL [10,16]. In relation to
the 35delG heterozygotes, there are contradictory results in the
literature [1,7,14]. Recent studies showed statistically signiﬁcant
differences between carriers’ audiograms and non-carriers’ only at
extra-high frequencies [1,14], despite previous studies having
described differences at 6000–8000 Hz. The ﬁndings in otoacoustic
emissions are non-conclusive in the literature [1,17,18].
The role of the Met34Thr variant in NSHL is much less
understood and the data available is controversial. Met34Thr
homozygotes or in compound heterozygosity with a known
pathogenic mutation on the other allele usually result in mild to
moderate NSHL [9,15,19]. A UK study found that carriers of the
Met34Thr variant presented a decrease at extra-high frequency
thresholds [14]. There are some reports of clinical ﬁndings in
Met34Thr carriers, therefore, this subject still remains controver-
sial [11,14,20–22].
The purpose of this study was to estimate the prevalence of
35delG and Met34Thr variants in a Portuguese children’s
community sample and to compare these frequencies with
nonsyndromic hearing-loss patients.
2. Participants and methods
2.1. Participants
2.1.1. Community participants
Generation XXI is a birth cohort of 8647 newborns recruited in
2005–2006 in the Porto Metropolitan Area, North of Portugal. The
recruitment occurred at all public maternity units, responsible for
95% of all births in the region, as described in a previous study [23].
Four years after birth, the whole cohort was invited to a follow-up
evaluation. For the present study, 545 of the participants attending
the follow-up evaluation were randomly selected, in order to study
the carrier rate of the most common mutation in the GJB2 gene in aPortuguese population—35delG. The sample size was calculated
based on the estimated frequency of the 35delG mutation in
Mediterranean populations—1 in 31 [5], with a level of signiﬁcance
of 5% and a power of 80%. The inclusion criterion was having at
least three generations of Caucasian Portuguese parental ancestry.
One of the most controversial variants associated to NSHL,
Met34Thr, was also studied as a secondary aim. Of the 545
selected participants, only 502 children were included in the study,
due to constraints regarding sample quality, which did not allow us
to get DNA ampliﬁcation by PCR (polymerase chain reaction).
2.1.2. Patients
Eighty-nine consecutive patients that attended the Clinic of
‘‘Hereditary Hearing-loss’’ in Saint John’s Hospital Center, from
June 2011 untill December 2014, with mild to profound NSHL,
from the North Region of Portugal, were invited to participate in
the study. Audiological evaluation was performed according to the
GenDeaf study group recommendations, using auditory brainstem
response tests (ABR) or pure tone audiometry (PTA) [24].
Syndromic hearing-loss and causes of acquired deafness were
excluded.
2.1.3. Ethics
All phases of the study complied with the Ethical Principles for
Medical Research Involving Human Subjects expressed in the
Declaration of Helsinki (World Medical Association, 2013). The
study was approved by the University of Porto’s Medical School/
Saint Jonh’s Hospital Center ethics committee and a signed
informed consent according to the Declaration of Helsinki was
obtained of all participants.
2.2. Methods
2.2.1. Genetic analysis
DNA samples of oral swabs were ampliﬁed by PCR (polymerase
chain reaction), using the following forward (Cx26F: 50-TCTTTTCCA-
GAGCAAACCGCC-30) and reverse (Cx26R: 50-TGAGCACGGGTTGCCT-
CATC-30) speciﬁc primers for the GJB2 gene exon 2. The enzyme used
was Type-it Microsatellite PCR kit from Qiagen. The cycling proﬁle
consisted of an initial denaturation at 95 8C for 5 min, followed by 35
cycles of 94 8C for 48 s, 63 8C for 48 s, 72 8C for 1 min and a ﬁnal
extension step at 72 8C for 30 min. PCR products puriﬁcation using
AmpureXPW was performed to remove the contaminants. The
sequencing samples were purchased as an outsourced service by
Primbio Research Institute, Exton, USA. The analysis of products was
performed on an automated sequencer (Applied BiosystemsW
3730xl DNA Analyzer) and the results were analyzed with Applied
BiosystemsW Sequencing Analysis v.5.4 software. All variants found
were then conﬁrmed in our department (ABI Prism 3500W). For those
with the 35delG mutation, the sequencing reaction was repeated
using the reverse primer in order to exclude the Met34Thr variant.
2.2.2. Statistical analysis
The statistical analyses were performed using SPSS Statistics
22W, GraphPadW and Epi InfoW softwares. The Chi-square test was
used to determine whether the allelic frequencies are in Hardy–
Weinberg equilibrium and to test for linkage disequilibrium
between the two minor variants. As expected values in some cells
of the contingency table were below 5, the p level used was
obtained from the Fisher’s exact test. Differences in the carrier
frequencies between the two groups were also tested by the Chi-
square test. The Chi-square test for trend was used to assess for a
possible dosage effect of the 35delG and Met34Thr variants upon
the association of hearing-loss. This Chi-square test for trend
assumed an additive genetic model, that is, the risk of a disease
conferred by an allele is increased additively [25,26].
Table 1
Results of 35delG and Met34Thr variants in NSHL patients and Generation XXI children. CI—conﬁdence interval; n/total—number of children with that characteristic in the
total of individuals.
Normal n/total (%) (95% CI) Heterozygote n/total (%) (95% CI) Homozygote n/total (%) (95% CI)
35delG NSHL patients 77/89 (86.50) (77.74–92.27%) 5/89 (5.60) (2.11–12.80%) 7/89 (7.90) (3.61–15.60%)
Generation XXI 491/502 (97.80) (96.07–98.82%) 10/502 (2.00) (1.03–3.68%) 1/502 (0.20) (0.01–1.24%)
Met34Thr NSHL patients 85/89 (95.50) (88.65–98.59%) 2/89 (2.20) (0.13–8.31%) 2/89 (2.20) (0.13–8.31%)
Generation XXI 492/502 (98.00) (96.32–98.95%) 10/502 (2.00) (1.03–3.68%) 0/502 (0.00) (0.00–0.92%)
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3.1. Frequency of 35delG and Met34Thr GJB2 variants in a Portuguese
sample
A total of 502 children from the Generation XXI cohort were
studied for the presence of the 35delG and Met34Thr variants in the
GJB2 gene. The results obtained and carrier rates are summarized in
Table 1. The 35delG mutation was found in 11 children, 10
heterozygotes (35delG/wild-type) and 1 homozygote (35delG/
35delG), indicating a carrier rate of 1 in 50 (95% Conﬁdence Interval
(CI) 1.03–3.68%). The case with homozygosity for 35delG/35delG
was subsequently conﬁrmed to have bilateral severe NSHL, through
self-reported data collected during the follow-up evaluation of
Generation XXI. None of the other participants presented a
phenotype similar to this one. Ten children presented heterozygosi-
ty for the Met34Thr variant, also indicating a carrier rate of 1 in 50.
No homozygous for Met34Thr or compound heterozygotes (35delG/
Met34Thr) were found in this study.
3.2. Frequency of 35delG and Met34Thr GJB2 variants in patients with
NSHL
Eighty-nine individuals with mild to profound NSHL were
studied for the presence of 35delG and Met34Thr variants in the
GJB2 gene. The results obtained and carrier rates are represented in
Table 1. The 35delG mutation was found in 12 patients, 5
heterozygotes (35delG/wild-type) and 7 homozygotes (35delG/
35delG), indicating a carrier rate of approximately 1 in 18 (95% CI
2.11–12.80%). Four individuals presented the Met34Thr variant, 2
in heterozygosity (Met34Thr/wild-type) and 2 in homozygosity
(Met34Thr/Met34Thr), estimating a carrier rate of approximately 1
in 44 (95% CI 0.13–8.31%). No compound heterozygosity was found
among the analyzed cases.
3.3. Comparison between the community participants and NSHL
patients
The analysis of the Hardy–Weinberg equilibrium (HWE) of the
genotypes within the Generation XXI cohort with a Chi-square test
showed evidence that this population is in HWE (p = 0.975 and
p = 0.998 for 35delG and Met34Thr alleles, respectively). There was
no evidence of linkage disequilibrium among the alleles (p = 0.910)
the Chi-square test for trend showed statistically signiﬁcant
dosage effects of both the 35delG mutation (p = 0.001) and the
Met34Thr variant (p = 0.050).
We also compared the carrier frequencies found in the NSHL
patients with those in children from Generation XXI. The
differences in the carrier frequencies between the two groups
were statistically signiﬁcant for the 35delG mutation (p = 0.001),
but not for the Met34Thr variant (p = 0.245).
4. Discussion
In this study, a group of 502 children from the Generation XXI
cohort and a group of 89 patients with mild to profound NSHL werescreened for the 35delG and Met34Thr GJB2 variants. Results
presented here conﬁrm that these variants are frequent in the
general population. In NSHL patients, a lower carrier frequency of
the Met34Thr variant (1 in 44) compared to 35delG (1 in 18) was
found, as previously described in a study from Snoeckx et al. [11].
In Generation XXI, similar carrier rates were found for the two
variants (1 in 50).
Although statistically signiﬁcant differences were found in the
35delG carrier frequencies (p = 0.001) for NSHL and Generation XXI
groups, the carrier frequencies of the Met34Thr variant were not
statistically different (p = 0.245). If this variant was unequivocally
associated with deafness, we would expect a statistically signiﬁ-
cant higher number of individuals with this variant in the NSHL
group compared to the general population. However, the
frequencies were similar (2.2% vs. 2.0%, respectively). The absence
of statistically signiﬁcant differences could be the result of
ascertainment bias toward more severe NSHL, as persons with
milder NSHL are less likely to request an audiological assessment
[11] or could result from low statistical power to ﬁnd association
between the variant and hearing-loss in our group of patients, due
to a low number of patients studied. It would be necessary to study
this variant in a larger number of patients with NSHL to better
characterize this potential association. However, the results of the
Chi-square test for trend suggest that the risk of hearing-loss
related to the Met34Thr variant may conform to an additive model
(p = 0.050), indicating that the Met34Thr variant may be a risk
factor for NSHL, directly related to this variant or acting as a
modifying allele, as previously described [27]. For the 35delG
mutation, the statistical evidence in favor of an additive pathogenic
effect is much more robust (p < 0.001).
The carrier rate of the 35delG variant found in the Portuguese
population cohort (1 in 50) was lower than the one estimated for
Portugal in the Gasparini et al. study (1 in 45) and for other
Mediterranean countries (1 in 35) [8,28]. However, this value is
similar to the average carrier rate of 35delG GJB2 variants in Europe
(1 in 51) [8].
To our knowledge, this is the ﬁrst study estimating the carrier
rate of the Met34Thr variant in the Portuguese population. The
carrier rate obtained in this study (1 in 50) is lower than rates
found in other European countries (1 in 17 in Estonia, 1 in 37 in UK
and 1 in 43 in France) [13]. Genetic studies of the GJB2 gene showed
that the Met34Thr variant is more prevalent in mid-west America
(0.765%), United Kingdom and Ireland (1.984%), but has a reduced
frequency or even absence in France, Spain, Italy and individuals of
Japanese ethnic origin [15]. Houseman et al. suggested that these
differences in populations’ carrier frequencies could be explained
by a single ancestral mutation occurring originally in the United
Kingdom or Ireland [15].
The effect of the Met34Thr variant on NSHL still remains
controversial. An autosomal dominant trait was ﬁrst described to
the Met34Thr variant [10]. Nevertheless, a second mutation in the
GJB2 gene has been identiﬁed, which is correlated with hearing-
loss, causing doubts about this autosomal dominant trait [22,27].
Subsequently, an autosomal recessive form of NSHL has been
suggested [15] and then, as several authors had reported normal
hearing in heterozygous carriers of the Met34Thr variant
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pathogenic [29–32]. These authors hypothesized that the frequent
presence of Met34Thr patients in NSHL patients could be due to the
high carrier rate of this variant in the general population [9,32].
More recently, studies combining genetic, clinical, biochemical,
electrophysiological properties and structural modeling studies
supported the hypothesis that Met34Thr is a pathological variant
associated with hearing impairment by showing that, at a cellular
level, despite the Cx26-Met34Thr protein being correctly synthe-
sized and targeted to the plasma membrane of HeLA cells, it
inefﬁciently forms intercellular channels that display abnormal
electrical activity and retain only 11% of the unitary conductance of
Cx26-wild-type [22,33]. The results of the additive model study
found in this work seem to corroborate this ﬁnding. A recent work
from our group showed evidence that this variant might correlate
with a dominant hearing-loss with incomplete penetrance and a
variable expression of the phenotype [34].
5. Conclusion
A high carrier frequency of the 35delG and Met34Thr GJB2
variants (1 in 50) was found in Generation XXI participants. Our
data suggests that the 35delG mutation has a clear association with
NSHL. Although no statistically signiﬁcant differences were found
between the carrier frequencies in the two groups for Met34Thr, it
seemed to conform to an additive model in hearing-loss.
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